Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Virus plus immunotherapy combo targets hard-to-treat neuroendocrine cancers

NCT ID NCT06889493

First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 21 times

Summary

This early-phase trial tests a virus that attacks cancer cells (SVV-001) together with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced neuroendocrine tumors or carcinomas that have worsened after standard treatment. The main goals are to find the safest dose and schedule, and to see if the combination can control the disease. About 36 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.